GSK has been granted a patent for substituted pyridine derivatives that act as inhibitors of DNA methyltransferase 1 (DNMT1) activity. These compounds can be used in the treatment of cancer, pre-cancerous syndromes, beta haemoglobinopathy disorders, and other diseases associated with inappropriate DNMT1 activity. GlobalData’s report on GSK gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights GSK plc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on GSK, Human telomerase RT biomarker was a key innovation area identified from patents. GSK's grant share as of September 2023 was 45%. Grant share is based on the ratio of number of grants to total number of patents.

Inhibitors of dna methyltransferase 1 activity in cancer treatment

Source: United States Patent and Trademark Office (USPTO). Credit: GSK plc

A recently granted patent (Publication Number: US11771711B2) discloses a series of compounds and their pharmaceutical compositions. The patent claims include various compounds of formulas (I), (II), (IV), and (V), as well as their corresponding glycine salts.

The patent claims also cover the crystalline and anhydrous forms of the glycine salts. Additionally, the patent claims encompass hydrated forms of the glycine salts, including monohydrates.

Furthermore, the patent claims include pharmaceutical compositions comprising the compounds or their pharmaceutically acceptable salts, along with one or more pharmaceutically acceptable excipients. These compositions can be used for various therapeutic purposes.

The patent claims also encompass combinations of the compounds or their salts with other active agents, providing potential synergistic effects or enhanced therapeutic outcomes.

Overall, this patent provides protection for a range of compounds and their pharmaceutical compositions, including different forms of glycine salts. These compounds and compositions have potential applications in the field of medicine and may offer new treatment options for various diseases and conditions.

To know more about GlobalData’s detailed insights on GSK, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies